KYMERA THERAPEUTICS INC (KYMR) Stock Price, Quote, News and Overview
NASDAQ:KYMR - Nasdaq - US5015751044 - Common Stock - Currency: USD
KYMR Quote, Performance and Key Statistics
36.81
-0.61 (-1.63%)
The current stock price of KYMR is 36.81 USD. In the past month the price decreased by -16.78%. In the past year, price decreased by -12.02%.
KYMR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About KYMR
Company Profile
Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company is headquartered in Watertown, Massachusetts and currently employs 184 full-time employees. The company went IPO on 2020-08-21. The firm is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. The firm's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. The company utilized its Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and it continues to apply its platform’s capabilities to additional therapeutic areas. Its clinical stage programs are IRAK4, STAT3, and MDM2, which each address high impact targets within biologically proven pathways, providing the opportunity to treat a range of immuno-inflammatory diseases, hematologic malignancies, and/or solid tumors.
Company Info
KYMERA THERAPEUTICS INC
500 North Beacon Street, 4Th Floor
Watertown MASSACHUSETTS 02139 US
CEO: Nello Mainolfi
Employees: 184
Company Website: https://www.kymeratx.com/
Investor Relations: https://investors.kymeratx.com/
Phone: 18572855314
KYMERA THERAPEUTICS INC / KYMR FAQ
What is the stock price of KYMERA THERAPEUTICS INC today?
The current stock price of KYMR is 36.81 USD. The price decreased by -1.63% in the last trading session.
What is the ticker symbol for KYMERA THERAPEUTICS INC stock?
The exchange symbol of KYMERA THERAPEUTICS INC is KYMR and it is listed on the Nasdaq exchange.
On which exchange is KYMR stock listed?
KYMR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for KYMERA THERAPEUTICS INC stock?
26 analysts have analysed KYMR and the average price target is 60.13 USD. This implies a price increase of 63.34% is expected in the next year compared to the current price of 36.81. Check the KYMERA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is KYMERA THERAPEUTICS INC worth?
KYMERA THERAPEUTICS INC (KYMR) has a market capitalization of 2.38B USD. This makes KYMR a Mid Cap stock.
How many employees does KYMERA THERAPEUTICS INC have?
KYMERA THERAPEUTICS INC (KYMR) currently has 184 employees.
What are the support and resistance levels for KYMERA THERAPEUTICS INC (KYMR) stock?
KYMERA THERAPEUTICS INC (KYMR) has a support level at 36.8 and a resistance level at 37.66. Check the full technical report for a detailed analysis of KYMR support and resistance levels.
Is KYMERA THERAPEUTICS INC (KYMR) expected to grow?
The Revenue of KYMERA THERAPEUTICS INC (KYMR) is expected to decline by -26.3% in the next year. Check the estimates tab for more information on the KYMR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy KYMERA THERAPEUTICS INC (KYMR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KYMR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KYMR, evaluating the profitability, health, valuation and growth aspects
- KYMERA THERAPEUTICS INC (KYMR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- KYMERA THERAPEUTICS INC (KYMR) Sales and EPS estimates to see what analysts future expectations are.
- KYMERA THERAPEUTICS INC (KYMR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- KYMERA THERAPEUTICS INC (KYMR) Insider and Institutional Ownership to learn about the owners and their transactions.
- KYMERA THERAPEUTICS INC (KYMR) Stock Chart to make your own analysis
- KYMERA THERAPEUTICS INC (KYMR) Latest news and press-releases to stay up to date.
Does KYMERA THERAPEUTICS INC (KYMR) stock pay dividends?
KYMR does not pay a dividend.
When does KYMERA THERAPEUTICS INC (KYMR) report earnings?
KYMERA THERAPEUTICS INC (KYMR) will report earnings on 2025-02-27, after the market close.
What is the Price/Earnings (PE) ratio of KYMERA THERAPEUTICS INC (KYMR)?
KYMERA THERAPEUTICS INC (KYMR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.27).
What is the Short Interest ratio of KYMERA THERAPEUTICS INC (KYMR) stock?
The outstanding short interest for KYMERA THERAPEUTICS INC (KYMR) is 12.04% of its float. Check the ownership tab for more information on the KYMR short interest.
KYMR Technical Analysis
KYMR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KYMR. While KYMR seems to be doing ok healthwise, there are quite some concerns on its profitability.
KYMR Financial Highlights
Over the last trailing twelve months KYMR reported a non-GAAP Earnings per Share(EPS) of -2.27. The EPS increased by 20.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.18% | ||
| ROE | -18.76% | ||
| Debt/Equity | 0 |
KYMR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to KYMR. The Buy consensus is the average rating of analysts ratings from 26 analysts.
For the next year, analysts expect an EPS growth of -15.36% and a revenue growth -26.3% for KYMR